Researchers discovered a novel therapeutic target for Parkinson's disease, the Aplp1 protein, which facilitates the spread of harmful alpha-synuclein proteins in the brain. Notably, an FDA-approved cancer drug targeting Lag3, a protein that interacts with Aplp1, has shown promise in blocking this spread in mouse models.
